Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a ...

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug ...

ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced ...

The Inducement Grant has a ten-year term and an exercise price per share of $9.97, which is equal to the closing price of Zenas’ common stock on the Grant Date. The Inducement Grant will vest over a ...

The net proceeds of the offering shall be used for working capital and general corporate purposes. Based on its current operating assumptions, Cyclacel expects this financing, together with Cyclacel’s ...

About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with ...

The Ensign Group, Inc. (Nasdaq: ENSG or “Ensign”), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational ...

On February 26, 2025, the NYSE American accepted a plan submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance. The ...

BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled ...

Poor Digestion and Gut Health: An unbalanced gut microbiome, frequent bloating, or sluggish digestion may impair nutrient ...

In connection with the offering, the Company will issue 1,180,877 shares of common stock (or pre-funded warrants to purchase shares of common stock) at a purchase price of $3.60 per share, priced ...

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules ...